Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 51,173

Document Document Title
WO/2019/009328A1
Provided is an iron nutritional status improving agent which uses killed lactobacillus and can be easily ingested in the form of supplement, etc. The iron nutritional status improving agent contains, as an active ingredient, killed bacte...  
WO/2019/010497A1
The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) rangin...  
WO/2019/007418A1
The present invention relates to the technical field of pharmacy, and specifically relates to a compound as represented by formula (I), and a pharmaceutically acceptable salt, an ester or stereoisomers thereof. R1, X1, X2, M, Ar, ring A,...  
WO/2019/009407A1
The problem addressed by the present invention is to provide a novel drug for treating haemorrhagic disorders which has a superior blood-coagulating effect, and a method for treating haemorrhagic disorders which uses said drug. Provided ...  
WO/2019/007015A1
The present invention provides application of a compound of a thioether acid structure in preparing drugs for treating or preventing cardiovascular and cerebrovascular diseases caused by platelet aggregation. Carbocisteine, fudosteine, e...  
WO/2019/010496A1
The present invention relates to method for pretreating a subject with severe von Willebrand disease prior to a surgical procedure comprising administering to the subject a dose ranging from about 20 IU/kg to about 60 IU/kg rVWF between ...  
WO/2019/004114A1
Provided is a production method for efficiently synthesizing a compound (1-2) which is an important intermediate in production of edoxaban. The method comprises dripping a compound (1-1) into a solution A that is obtained by causing a re...  
WO/2019/004155A1
Provided is a tablet which is highly resistant against impact and abrasion and in which defects in a cup portion and an edge can be effectively avoided. A tablet 1 which comprises a cup portion 12 formed on the upper and/or lower sides o...  
WO/2019/003433A1
The present invention provides: a novel benzazepine compound which is represented by formula (1) and has vasopressin V1a and V2 antagonism, or a salt thereof; and a pharmaceutical use thereof. [In formula, R1 represents optionally substi...  
WO/2018/234565A1
The present invention is directed to the use of cangrelor for the treatment and/or prevention of shunt thrombosis in patients suffering congenital heart diseases undergoing shunt surgery.The invention is also directed to the use of cangr...  
WO/2018/234861A1
The present invention concerns the use of plasminogen, a variant thereof, or an analog thereof having a plasminogen activity, for the prevention or treatment of a condition or a disease that is characterized with an increased PAI-1 level...  
WO/2018/234518A1
The present invention relates to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) capable of binding to blood coagulation Factor VIII (FVIII) for use in reducing the immunogenicity of Factor VIII (FVIII) where...  
WO/2018/237243A1
Disclosed is the use of garcinol for the therapeutic management of ER stress. More specifically, the invention discloses the ability of garcinol in decreasing ER stress and mitigating toxicity by reducing protein aggregation and decreasi...  
WO/2018/229739A1
This dose determination program is a computer-executed program that determines the dose of an erythropoiesis-stimulating agent, and that executes, in a computer, a step (S1) for acquiring a predetermined target hemoglobin concentration t...  
WO/2018/232006A1
The invention relates to mRNA therapy for the treatment of Hemophilia A. mRNAs for use in the invention, when administered in vivo, encode Factor VIII, isoforms thereof, functional fragments thereof, and fusion proteins comprising Factor...  
WO/2018/227755A1
Provided are a method for specifically repairing, by using a base editing method, A>G pathogenic mutations causing β-thalassemia of humanms, a gRNA specifically targeting the mutations, and a base editing protein. By means of the method...  
WO/2018/225673A1
Disclosed are: a method for manufacturing a therapeutic composition containing mammalian cells, said method comprising dispersing the mammalian cells in an aqueous glucose solution having a concentration of about 3-10% or Ringer's acetat...  
WO/2018/226998A1
The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as ca...  
WO/2018/221480A1
[Problem]To provide a novel technique, which is more effective in the treatment of portal vein thrombosis. [Solution] This portal vein thrombosis therapeutic agent contains an antithrombin III as an active ingredient, is administered to ...  
WO/2018/222792A1
The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to optimized polynucleotide sequences ...  
WO/2018/221543A1
The present invention provides: an I-type crystal of (E)-2-(7-trifluoromethyl chromane-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaph thalene-1-yl)acetamide having an excellent TRPV1 antagonistic activity; a medication and a medicat...  
WO/2018/221562A1
According to the present invention, it is found that dopamine D2-like receptor agonists acts on a dopamine D2-like receptor in an activated Th cell and thereby inhibits the production of Interleukin-8 (IL-8).  
WO/2018/221433A1
Provided is a novel compound, and a pharmaceutically acceptable salt thereof, that has an action of reducing blood sugar and the like, and that is useful as a therapeutic and/or preventive medicine for diseases such as diabetes. Provided...  
WO/2018/221291A1
[Problem] Various side effects have been reported for conventional therapeutic drugs for hyperactive bladder, and a prophylactic or therapeutic agent for hyperactive bladder without causing side effects is desired. [Solution] Provided is...  
WO/2018/215917A1
A Direct Sodium Removal method, apparatus and solution for treating patients in heart failure, and having a glomerular filtration rate greater than 15 mL/min/1.73 m2, or residual kidney function corresponding to normal to CKD Stage 4, is...  
WO/2018/217638A1
Provided are methods for clinical treatment of a protein-losing enteropathy, such as lymphangiectasia, using an anti-C5 antibody, or antigen binding fragment thereof, in patients (e.g., pediatric patients).  
WO/2018/214860A1
The present invention provides a method and pharmaceutical composition for treating aplastic anemia, and specifically provides applying an S1PR1 signal inhibitor to an object in need to treat aplastic anemia.  
WO/2018/218133A1
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure...  
WO/2018/211487A1
Methods of selecting umbilical cord blood units for ex-vivo expansion, separation of CD133+/CD34+ positive and uncultured CD133+/CD34+ negative fractions, methods for expanding the selected CD133+/CD34+ fraction, selection of expanded po...  
WO/2018/211509A3
Methods of selecting umbilical cord blood units for ex-vivo expansion, separation of CD133+/CD34+ positive and uncultured CD133+/CD34+ negative fractions, methods for expanding the selected CD133+/CD34+ fraction, selection of expanded po...  
WO/2018/207565A1
The present invention addresses the problem of providing: a separation substrate which has a high inhibition rate of megakaryocytes and a high permeability of platelets; a cell separation filter using the same; and a platelet producing m...  
WO/2018/205928A1
The present invention relates to indolizine derivatives and applications thereof in medicine. In particular, disclosed in the present invention are novel substituted indolizine derivatives of formula I, or isotopically-labeled compounds ...  
WO/2018/201572A1
A traditional Chinese medicine composition for treating hematuria, prepared by employing the following ingredients: 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba Eq...  
WO/2018/199214A1
The present invention provides a method for improving or controlling the plasma half-life and/or bioavailability of coagulation factor IX (FIX), the method being characterized by modifying the GLA domain. Examples of such modification in...  
WO/2018/199166A1
The purpose of the present invention is to provide: compounds having a TrkA inhibiting effect, or pharmacologically acceptable salts thereof, or solvates of these; pharmaceutical compositions characterized by containing these as an activ...  
WO/2018/196757A1
The present invention relates to the field of medicines, and specifically relates to a 4-aminopyrimidine compound having a structural feature represented by formula (I), or pharmaceutically acceptable salts thereof, a preparation method ...  
WO/2018/199291A1
The purpose of the present invention is to discover a novel compound having an excellent β-lactamase-inhibiting activity, and to provide a useful prophylactic or therapeutic agent for bacterial infectious diseases which comprises a comb...  
WO/2018/191801A1
A method for producing a fibrin biopolymer, means for applying said fibrin biopolymer, and a method for applying said fibrin biopolymer, according to which dehydration and grinding of biopolymer components (serine protease purified from ...  
WO/2018/188635A1
A cerasome delivery system for use in the targeted activation of a CD44 molecule, a preparation method and use thereof: a surface of a cerasome is partially modified by a targeting ligand, the targeting ligand being a ligand which may sp...  
WO/2018/189559A1
The present invention concerns the antiplatelet activity of Acanthus mollis seeds' methanolic extract and the identification of its constituents responsible for this effect, using the techniques LTA, NMR, HPLC and LC-MS, respectively. We...  
WO/2018/186322A1
The present invention provides anti-MASP-1 (mannan-binding lectin (MBL)-associated serine protease 1) antibodies and methods of using the same. In some embodiments, an anti-MASP-1 antibody of the invention binds to MASP-1 but does not bi...  
WO/2018/187493A1
Compositions and methods for fetal or in utero delivery of active agents are provided. The compositions are most typically administered intravenously via the vitelline vein, umbilical vein, or directly into the amniotic cavity of a pregn...  
WO/2018/181987A1
Provided is an adsorbent for indole and derivatives thereof that selectively adsorbs indole and derivatives thereof (particularly indole). A copolymer synthesized by mixing structural units based on each monomer at an optimal ratio was d...  
WO/2018/181380A1
To provide an edible composition for intestinal bacteria which ameliorates intestinal flora (intestinal bacterial flora) and promotes the diversity thereof so as to contribute to human health. A composition comprising: a natural dietary ...  
WO/2018/178141A1
The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)- tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solv...  
WO/2018/181870A1
The present inventors verified the coagulation promoting effect of multispecific antigen binding molecules, said molecules replacing the function of FVIII, using blood and plasma collected from patients with FIX abnormality. As a result,...  
WO/2018/178142A1
The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio...  
WO/2018/177993A1
The invention relates, inter alia, to compounds of general formula (I). The invention also relates to methods for synthesizing the compounds of formula (I). The compounds according to the invention are in particular suitable for controll...  
WO/2018/179974A1
A sterilized peritoneal dialysis solution that comprises an acidic first solution containing icodextrin and a second solution containing 300-3,000 mg/L of L-histidine and a pH controller, wherein: the first solution contains no pH contro...  
WO/2018/178144A1
The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)- tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:1.51 to 1:2.5 and/or hydrates and/or solvates thereof...  

Matches 1 - 50 out of 51,173